1-6 of 6
Authors: James Waisman
Save search
Sort by
Journal Article

Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis

PDF
Alexis LeVee and others
The Oncologist, Volume 29, Issue 7, July 2024, Pages 566–574, https://doi.org/10.1093/oncolo/oyae064
Published: 24 April 2024
Journal Article

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer

PDF
Yuan Yuan and others
The Oncologist, Volume 28, Issue 7, July 2023, Pages e498–e507, https://doi.org/10.1093/oncolo/oyad026
Published: 06 April 2023
Journal Article

Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer

PDF
Xuan Ge and others
The Oncologist, Volume 28, Issue 7, July 2023, Pages e488–e492, https://doi.org/10.1093/oncolo/oyad024
Published: 21 March 2023
Journal Article

A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer

PDF
Yuan Yuan and others
The Oncologist, Volume 26, Issue 2, February 2021, Pages 99–e217, https://doi.org/10.1002/onco.13583
Published: 24 November 2020
Journal Article

Phase II Trial of Neoadjuvant Carboplatin and Nab‐Paclitaxel in Patients with Triple‐Negative Breast Cancer

PDF
Yuan Yuan and others
The Oncologist, Volume 26, Issue 3, March 2021, Pages e382–e393, https://doi.org/10.1002/onco.13574
Published: 08 November 2020
Journal Article

Association of Pre‐Chemotherapy Peripheral Blood Pro‐Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer

PDF
Yuan Yuan and others
The Oncologist, Volume 22, Issue 10, October 2017, Pages 1189–1196, https://doi.org/10.1634/theoncologist.2016-0391
Published: 30 May 2017